{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-187579","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2023-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.405628+00:00","generated_at":"2026-06-13T07:40:48.312193+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.88,"calibrated_materiality_score":0.88,"confidence":"high","headline":"Acumen's ACU193 Phase 1 meets endpoints; plaque reduction up to 25%, low ARIA-E rate","bullets":["60 mg/kg Q4W cohort showed 25% mean amyloid plaque reduction at day 63; 25 mg/kg Q2W showed 20% at day 70.","Overall ARIA-E rate 10.4% (5/48); symptomatic ARIA-E 2.1% (1/48); no drug-related serious adverse events.","Statistically significant dose-proportional PK and near-maximal target engagement of toxic AβOs in CSF.","Monthly dosing supported by pharmacokinetic and CSF data; company plans FDA interaction in Q4 2023.","INTERCEPT-AD enrolled 60 early-AD participants; results to be submitted for peer-reviewed publication."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-187579","json":"https://secwatch.observer/filing/0001193125-23-187579.json","markdown":"https://secwatch.observer/filing/0001193125-23-187579.md","text":"https://secwatch.observer/filing/0001193125-23-187579.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000119312523187579/0001193125-23-187579-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000119312523187579/d518971d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T07:40:48.312193+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}